Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment

Eur Heart J. 1996 Oct;17(10):1503-5. doi: 10.1093/oxfordjournals.eurheartj.a014713.

Abstract

Background: The aim of the study was to test if plasma levels of thrombomodulin could predict mortality in 209 patients on long-term anticoagulant treatment followed up for 3.8 years.

Methods and results: The thrombomodulin level was 60.9 +/- 29.8 micrograms.l-1 for all 45 patients who died and 60.5 +/- 30.5 micrograms.l-1 for the 38 vascular deaths, compared to 52.3 +/- 20.7 micrograms.l-1 for the 164 survivors. We found that, in Cox regression analyses, all-cause (P = 0.025) and vascular mortality (P = 0.042) was significantly and independently associated with increased levels of thrombomodulin.

Conclusions: The level of plasma thrombomodulin can predict all-cause and vascular mortality in patients on long-term anticoagulant treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / mortality*
  • Cause of Death*
  • Follow-Up Studies
  • Humans
  • Long-Term Care
  • Prothrombin Time
  • Regression Analysis
  • Risk
  • Survival Analysis
  • Sweden / epidemiology
  • Thromboembolism / blood
  • Thromboembolism / drug therapy
  • Thromboembolism / mortality*
  • Thrombomodulin / blood*

Substances

  • Anticoagulants
  • Thrombomodulin